Brief: Arch Biopartners - Health Canada Has Approved Amendment To CATCO Protocol To Include Lsalt Peptide In New Dosing Arm Of Trial
14/02/2022 12:34
Feb 14 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS INC - HEALTH CANADA HAS APPROVED
AMENDMENT TO
CATCO PROTOCOL TO INCLUDE LSALT PEPTIDE IN A NEW DOSING ARM OF
TRIAL
* ARCH BIOPARTNERS INC - HEALTH CANADA APPROVED AMENDMENT TO
CATCO
PROTOCOL TO INCLUDE ITS LEAD DRUG CANDIDATE, LSALT PEPTIDE IN
NEW DOSING ARM OF TRIAL
Source text for Eikon: ID:nGNXbhnrtk
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide